NasdaqCM:NKTRPharmaceuticals
Will REZOLVE-AA Class Actions Over Trial Disclosures Change Nektar Therapeutics' (NKTR) REZPEG Narrative?
Nektar Therapeutics recently faced multiple securities class action filings and investigations alleging misleading disclosures around enrollment protocols and outcomes in its REZOLVE-AA Phase 2b trial, which previously failed to reach statistical significance.
These legal challenges focus on whether management accurately represented the integrity of a key clinical program, raising fresh questions about governance, disclosure practices, and oversight of trial execution.
We’ll now examine how...